Immuno-Oncology: A New Class of Drugs (2018)
Complimentary CME Webinar!
THURSDAY, SEPTEMBER 27, 2018 | 7:00- 8:00 P.M. ET
To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. This is the first in a series of 4 webinars.
The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Immuno-Oncology: A New Class of Drugs is the first live webinar in the 4-part series of live webinars. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal Antibodies" and "Checkpoint Inhibitors".
Webinar #1: Immuno-Oncology: A New Class of Drugs - Thursday, September 27, 2018, 7-8 p.m. ET
Webinar #2: Immuno-Oncology: A Focus on Bladder Cancer- Tuesday, October 9, 2018, 7-8 a.m. ET
Webinar #3: Immuno-Oncology: A Focus on Kidney Cancer- Thursday, October 25, 2018, 7-8 p.m. ET
Webinar #4: Immuno-Oncology: A Focus on Prostate Cancer- TBA
This educational series is supported by independent educational grants from:
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Advanced Practice Provider
- Non-Urologist (MD or DO)
- This activity may also be of interest to other clinicians and health care professionals involved in the treatment of patients impacted by GU cancer.
At the conclusion of this activity, participants will be able to:
1. Restate the role of the immune system in cancer prevention and elimination.
2. Discuss the effects of immune system checkpoint inhibitors on the immunosuppressive activity of tumor cells.
3. Review clinical investigations into the efficacy of immune system checkpoint inhibitors in the treatment of GU cancers.
Thursday, September 27, 2018
7:00 - 7:05 p.m. Welcome - Costas Lallas, MD
7:05 - 7:10 p.m. Pre-Test - Costas Lallas, MD
7:10 - 7:50 p.m. Immunotherapy: Tumor Immunobiology, Drug Availability and Mechanisms of Action - Joshua Meeks, MD, PhD
7:50 - 8:00 p.m. Post- Test - Costas Lallas, MD
Immuno-Oncology: A New Class of Drugs is the first live webinar in 4-part series of live webinars. It will be held on Thursday, September 27, 2018 at 7:00 p.m. ET
This live webinar will be conducted via Adobe Connect with a toll-free teleconference available for the audio component. Participants only need a standard web browser to participate. Instructions for joining this program, in two easy steps, can be found below. Please plan to join this session 15 minutes early to ensure that you are able to access the virtual classroom. You may test your system ahead of time by clicking here.
AUA ACCREDITATION INFORMATION
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence‐based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point‐counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only
- in procedural demonstrations
- Divestiture of the relationship by faculty
OFF‐LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES
The audience is advised that this continuing medical education activity may contain reference(s) to off‐label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation